A Pilot Study of Antibiotic Regimens for Infections Caused by Acinetobacter baumannii in a Secondary Hospital in Thailand

Figures & data

Table 1 Characteristics of 32 Patients Admitted to Phang-Nga Hospital During 1 January 2019 and 31 May 2020 Due to Acinetobacter baumannii Infection

Variables	Number (%)
Gender
Male	17 (53.1)
Female	15 (46.9)
Average age (Range) (Year)	63.6 (18–97)
Main diagnosis
Respiratory tract infection	9 (28.1)
Wound infection	8 (25.0)
Sepsis	4 (12.5)
Stroke	3 (9.4)
Cancer	3 (9.4)
Others	5 (15.6)
Site of infection
Lung	16 (50.0)
Urinary tract	4 (12.5)
Extremities	3 (9.4)
Unknown	9 (28.1)
Site of Acinetobacter baumannii isolation
Sputum	16 (50.0)
Blood	7 (21.9)
Pus	8 (25.0)
Urine	1 (3.1)
Charlson Comorbidity Index (Range)	3.67 (1–6)
ICU admission	8 (25.0)
Septic shock incidence	9 (28.1)
Mechanical ventilator use	11 (34.4)

Table 2 Antibiotic Regimens as the Empirical Therapy for the Infection of Acinetobacter baumannii in 32 Patients

Antibiotic Regimen		Number of Case
Monotherapy	Beta-lactam/Beta-lactamase inhibitor	7
	Cephalosporin	5
	Carbapenem	5
Combination therapy	Cephalosporin + Macrolide	4
	Carbapenem + Fluoroquinolone	3
	Cephalosporin + Metronidazole	2
	Carbapenem + Vancomycin	2
	Cephalosporin + Clindamycin	1
	Cephalosporin + Vancomycin + Clindamycin	1
	Carbapenem + Vancomycin + Fosfomycin	1
	Carbapenem + Fluoroquinolone + Beta-lactam/Beta-lactamase inhibitor + Colistin	1

Table 3 Antibiotic Regimens as the Definitive Therapy for the Infection of Acinetobacter baumannii in 32 Patients

Antibiotic Regimen		Number of Case
Monotherapy	Carbapenem	9
	Cephalosporin	5
	Beta-lactam/Beta-lactamase inhibitor	4
	Fluoroquinolone	1
Combination therapy	Colistin + Carbapenem	2
	Colistin + Carbapenem + Beta-lactam/Beta-lactamase inhibitor	3
	Cephalosporin + Macrolide	2
	Beta-lactam/Beta-lactamase inhibitor + Fluoroquinolone	1
	Carbapenem + Macrolide	1
	Carbapenem + Fluoroquinolone	1
	Carbapenem + Vancomycin + Fosfomycin	1
	Carbapenem + Vancomycin + Colistin	1
	Cephalosporin + Vancomycin + Clindamycin	1

Table 4 Clinical Cure and Mortality Rates of 32 Patients Receiving Antibiotic Regimens for the Treatment of Acinetobacter baumannii Infection

Antibiotic Regimen	Number of Case (%)	Number of Clinical Cure (%)	Number of Death (%)
All regimens	32 (100.0)	19 (45.9)	11 (43.4)
Monotherapy regimens
Cephalosporin	5 (15.6)	5 (100.0)	0 (0.0)
Carbapenem	9 (28.1)	7 (77.8)	2 (22.2)
Beta-lactam/Beta-lactamase inhibitor	4 (12.5)	2 (50.0)	2 (50.0)
Combination therapy regimens with colistin	6 (18.8)	1 (16.7)	4 (66.7)
Combination therapy regimens with carbapenem	9 (28.1)	1 (11.1)	7 (77.8)
Combination therapy regimens without colistin and carbapenem	4 (12.5)	4 (100.0)	0 (0.0)

Note: All combination regimens with colistin included meropenem, and then were counted twice.